Machine Learning (PIERS-ML) model and the logistic regression-based fullPIERS model, consecutive performance deteriorates over time.
In persistent pulmonary hypertension of the newborn (PPHN), illness severity scores have high accuracy and can predict mortality.
The following is a summary of "Association between serum creatinine—to—albumin ratio and 28-day mortality in intensive care ...
Contrast-enhanced conebeam breast CT imaging features can help identify lymphovascular invasion status in patients with ...
Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a ...
The FDA has approved the biologics license applications for Ospomyv and Xbryk, biosimilars to Prolia and Xgeva, respectively.
Researchers indicate that the Lumipulse p-tau217 assay may reduce over 50% of lumbar punctures performed for diagnosing ...
The following is a summary of “Impact of age and mean intracranial pressure on the morphology of intracranial pressure waveform and its association with mortality in traumatic brain injury,” published ...
Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for OSPOMYV™ (denosumab-dssb; SB16; 60 mg pre-filled ...
US PMIs falter; US sentiment drops; US inflation expectations rise; Japan inflation up; Japan PMIs rise; India still expanding fast; commodity prices weaken; UST 10yr at 4.42%; gold and oil down; NZ$1 ...
Zacks Small Cap Research on MSN3d
RANI: Impressive Bioavailability for RT-116
RANI READ THE FULL RANI RESEARCH REPORT On February 5 th , Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) shared its preclinical readout from the RT-116 study demonstrating successful oral delivery of ...
Samsung Bioepis Co., Ltd. today announced that the European Commission (EC) has granted marketing authorization for OBODENCEtm (60mg pre-filled syringe) and XBRYKtm (120mg vial), denosumab biosimilars ...